Sign in
CompletedNo phase

Effect of Clinical Pharmacist-Led Pharmaceutical Care in Major Depressive Disorder

Key facts

Who runs it
Marmara University
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
186 people enrolled
Started
25 Dec 2024
Ended
30 Jun 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Clinical Pharmacist-Led Pharmaceutical Care
Record updated
16 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adults aged 18-65 years
  • Diagnosis of major depressive disorder (MDD) by a psychiatrist according to DSM-5 criteria
  • Receiving maintenance antidepressant treatment for at least one month
  • Ability to communicate effectively in Turkish
  • Willingness to participate in the study and provision of written informed consent
  • Availability to complete the scheduled follow-up assessments

Who cannot take part

  • Drug or substance dependence
  • History of bipolar disorder, psychotic disorders, or other severe psychiatric disorders that could interfere with study participation
  • Active cancer
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized controlled trial evaluated the effects of a six-month clinical pharmacist-led pharmaceutical care intervention on medication adherence, beliefs about medicines, and health-related quality of life in adults diagnosed with major depressive disorder (MDD) receiving antidepressant treatment.

Read full original descriptionShow less

A total of 186 participants were randomized in a 1:1 ratio to receive either structured pharmaceutical care in addition to usual psychiatric care or usual psychiatric care alone. Of these, 170 participants completed the six-month follow-up.

The intervention included individualized patient counseling, medication review, identification and management of medication-related problems, and telephone follow-up every two weeks.

Medication adherence was assessed using the Medication Adherence Report Scale (MARS-5), beliefs about medicines using the Turkish Beliefs about Medicines Questionnaire (BMQ-T), and health-related quality of life using the EQ-5D-3L and EQ-VAS. Assessments were conducted at baseline, Month 3, and Month 6.

The 2 groups in the trial

  • Clinical Pharmacist-Led Pharmaceutical CareTreatment being tested

    Participants assigned to this group received structured clinical pharmacist-led pharmaceutical care in addition to usual psychiatric care for six months. The intervention included individualized patient education and counseling, medication review, identification and management of medication-related problems, monitoring of adverse effects, and telephone follow-up every two weeks.

  • Usual Psychiatric CareNo study treatment, for comparison

    Participants assigned to the control group received usual psychiatric care, including routine clinical follow-up and antidepressant treatment as prescribed by their treating psychiatrist. No additional structured clinical pharmacist-led pharmaceutical care intervention was provided during the six-month study period. Outcome assessments were conducted at baseline, Month 3, and Month 6.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Clinical Pharmacist-Led Pharmaceutical Care on Medication Adherence, Beliefs About Medicines, and Health-Related Quality of Life in Patients With Major Depressive Disorder: A Randomized Controlled Trial
Record updated
16 November 2026